FOXO4-DRI

FOXO4-DRI (also known as FOXO4-D-Retro-Inverso, Senolytic peptide) is a prominently researched experimental compound classified strictly within the Senolytic Peptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it d-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. In normal cells, FOXO4 retains p53 in the nucleus preventing apoptosis — a mechanism senescent cells exploit for survival. FOXO4-DRI competitively binds FOXO4, freeing p53 to migrate to mitochondria, triggering apoptosis selectively in senescent cells. Results in clearance of senescent cell burden, reduction of the senescence-associated secretory phenotype (SASP), and tissue rejuvenation markers in aged mice. with a documented biological half-life of roughly 2 hours, In preclinical investigative trials and independent academic studies, researchers utilizing FOXO4-DRI have documented significant, quantifiable biological outcomes, primarily focusing on senescent cell elimination (senolytics), longevity, tissue rejuvenation, sasp reduction. Typical research protocols investigate administering 5000 to 10000mcg via subq pathways pulsed — 3 days per week, per mouse study protocol. However, it is critically important to understand that while FOXO4-DRI demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.